Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals

Mar 01 2020

• By Bridget Silverman

Keeping Track Feature image — • Source: Shutterstock

Related Content

Keeping Track: Intercept Submits OCA For NASH; Zogenix’ Fintepla Returns; US FDA Approves Bavarian Nordic Vaccine

Sep 29 2019

New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza

Sep 29 2019

Can Takeda's Alunbrig Take On Roche's Alecensa In First-Line ALK-Positive Lung Cancer?

Sep 27 2018

Biohaven’s Oral CGRP Inhibitor Nurtec ODT Approved In The US For Acute Migraine

Feb 28 2020

Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market

Feb 27 2020

Eli Lilly’s Trulicity’s Broad CV Label Spotlights GLP-1 Rivalry

Feb 24 2020

Novartis In Line For Ofatumumab MS Approval In June

Feb 24 2020

Almirall’s Dermatology Pitch Takes Shape

Aug 04 2019

Related Companies

Biohaven Pharmaceutical Holding Company Ltd.

H. Lundbeck A/S

Acacia Pharma Group plc

Eli Lilly and Company

Esperion Therapeutics, Inc.

GSK plc

Takeda Pharmaceutical Co. Ltd.

Novartis AG

Athenex, Inc.

Innocoll Holdings Limited

Allergan plc

Almirall SA

Additional Topics

United States Approvals Drug Review Drug Approval Standards Regulation US FDA Performance Tracker Dermatology Neurology Metabolic Disorders Cancer BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window